Anagram Therapeutics Completes Dosing Study of ANG003, a Broad-Spectrum Oral Enzyme Replacement Therapy, in People with Cystic Fibrosis
https://t.co/6IwZ72gMIg
@CF_Foundation@NatPancFdn
Anagram Therapeutics is thrilled to announce Expansion of Joint Product Development Collaboration with ATUM to Accelerate Development of Orally Delivered Enzymes for Malabsorption and Nutrient Metabolism Disorders
https://t.co/pm1mCDEw7N